Indicators
Indicators
Value
Direction
MACD(12,26,9)
1.449
Buy
RSI(14)
72.467
Buy
STOCH(KDJ)(9,3,3)
85.536
Buy
ATR(14)
2.180
Low Volatility
CCI(14)
168.478
Buy
Williams %R
7.782
Overbought
TRIX(12,20)
0.636
Sell
StochRSI(14)
98.241
Overbought
Lantheus Holdings Inc
LNTH66.570USD
-0.050-0.08%
Close 12/15, 16:00（ET）Quotes delayed by 15 min
4.41BMarket Cap
27.02P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Lantheus Holdings Inc
Currency: USD Updated: 2025-12-15Key Insights
Lantheus Holdings Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 2/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 80.92.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Lantheus Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
13
analysts
Buy
Current Rating
80.923
Target Price
+29.96%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Lantheus Holdings Inc Highlights
StrengthsRisks
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 64.04% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.53B.
Overvalued
The company’s latest PE is 27.02, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 78.96M shares, decreasing 9.90% quarter-over-quarter.
Held by Private Capital
Star Investor Private Capital holds 560.66K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.29.
Financial Health
Currency: USD Updated: 2025-12-15The current financial score of Lantheus Holdings Inc is 8.52, ranking 36/208 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 384.01M, representing a year-over-year increase of 1.39%, while its net profit experienced a year-over-year increase of 78.82%.
Score
Financials
8.70
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
9.40
Growth Potential
7.23
Shareholder Returns
7.27
Lantheus Holdings Inc's Company Valuation
Currency: USD Updated: 2025-12-15The current valuation score of Lantheus Holdings Inc is 8.80, ranking 5/208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 27.02, which is 648.18% below the recent high of 202.19 and 1500.33% above the recent low of -378.42.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 2/208
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-15The current earnings forecast score of Lantheus Holdings Inc is 7.85, ranking 114/208 in the Healthcare Equipment & Supplies industry. The average price target for Lantheus Holdings Inc is 77.00, with a high of 130.00 and a low of 60.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
80.923
Target Price
+29.96%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
112
Total
6
Median
9
Average
Company name
Ratings
Analysts
Lantheus Holdings Inc
LNTH
13
Medtronic PLC
MDT
35
Stryker Corp
SYK
32
Dexcom Inc
DXCM
31
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
23
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-15The current price momentum score of Lantheus Holdings Inc is 9.27, ranking 26/208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 72.05 and the support level at 56.45, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
63.598
Buy
MA10
62.375
Buy
MA20
59.210
Buy
MA50
56.722
Buy
MA100
56.736
Buy
MA200
72.740
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-15The current institutional shareholding score of Lantheus Holdings Inc is 10.00, ranking 1/208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 119.07%, representing a quarter-over-quarter decrease of 1.50%. The largest institutional shareholder is The Vanguard, holding a total of 6.92M shares, representing 10.44% of shares outstanding, with 3.39% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Janus Henderson Investors
Farallon Capital Management, L.L.C.
Fidelity Management & Research Company LLC
State Street Investment Management (US)
Geode Capital Management, L.L.C.
Dimensional Fund Advisors, L.P.
Reinhart Partners, LLC
1
2
Risk Assessment
Currency: USD Updated: 2025-12-15The current risk assessment score of Lantheus Holdings Inc is 6.93, ranking 49/208 in the Healthcare Equipment & Supplies industry. The company's beta value is -0.11. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
-0.11
VaR
+4.29%
240-Day Maximum Drawdown
+54.45%
240-Day Volatility
+59.89%
Return
Best Daily Return
60 days
+5.58%
120 days
+5.76%
5 years
+39.12%
Worst Daily Return
60 days
-6.19%
120 days
-28.58%
5 years
-28.58%
Sharpe Ratio
60 days
+2.92
120 days
-0.38
5 years
+0.74
Risk Assessment
Maximum Drawdown
240 days
+54.45%
3 years
+59.46%
5 years
+59.46%
Return-to-Drawdown Ratio
240 days
-0.46
3 years
+0.08
5 years
+0.83
Skewness
240 days
-2.83
3 years
+0.29
5 years
+1.24
Volatility
Realised Volatility
240 days
+59.89%
5 years
+57.05%
Standardised True Range
240 days
+4.90%
5 years
+4.25%
Downside Risk-Adjusted Return
120 days
-37.10%
240 days
-37.10%
Maximum Daily Upside Volatility
60 days
+31.50%
Maximum Daily Downside Volatility
60 days
+23.74%
Liquidity
Average Turnover Rate
60 days
+2.23%
120 days
+1.88%
5 years
--
Turnover Deviation
20 days
+129.43%
60 days
+40.52%
120 days
+18.33%
Peer Comparison
Healthcare Equipment & Supplies
Lantheus Holdings Inc
LNTH
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LIVN
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
AORT
8.55 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tactile Systems Technology Inc
TCMD
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Becton Dickinson and Co
BDX
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Align Technology Inc
ALGN
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Lantheus Holdings Inc?
The TradingKey Stock Score provides a comprehensive assessment of Lantheus Holdings Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Lantheus Holdings Inc’s performance and outlook.
How do we generate the financial health score of Lantheus Holdings Inc?
To generate the financial health score of Lantheus Holdings Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Lantheus Holdings Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Lantheus Holdings Inc.
How do we generate the company valuation score of Lantheus Holdings Inc?
To generate the company valuation score of Lantheus Holdings Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Lantheus Holdings Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Lantheus Holdings Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Lantheus Holdings Inc.
How do we generate the earnings forecast score of Lantheus Holdings Inc?
To calculate the earnings forecast score of Lantheus Holdings Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Lantheus Holdings Inc’s future.
How do we generate the price momentum score of Lantheus Holdings Inc?
When generating the price momentum score for Lantheus Holdings Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Lantheus Holdings Inc’s prices. A higher score indicates a more stable short-term price trend for Lantheus Holdings Inc.
How do we generate the institutional confidence score of Lantheus Holdings Inc?
To generate the institutional confidence score of Lantheus Holdings Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Lantheus Holdings Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Lantheus Holdings Inc.
How do we generate the risk management score of Lantheus Holdings Inc?
To assess the risk management score of Lantheus Holdings Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Lantheus Holdings Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Lantheus Holdings Inc.
